Clinically significant response on positive symptoms at least 50% MS improvement · schizophrenia
Adjunctive lithium + antipsychotics showed no clear difference in clinically significant response on positive symptoms at least 50% MS… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
Kidney dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Thyroid dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes tardive dyskinesia: no clinically important improvement compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes tardive dyskinesia: deterioration of symptoms compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
General mental state: relapse · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes general mental state: relapse compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
RR 3 [0.16, 57.36]
1 study · 8 participants
Very low
Adverse effect: any ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
RR 0.33 [0.06, 1.99]
1 study · 8 participants
Very low
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
Adjunctive carbamazepine + antipsychotics showed no clear difference in no clinically important change in general mental state Scale used:… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Depressive symptoms · patients with schizophrenia
1 finding from 1 review
Aggression · patients with schizophrenia
1 finding from 1 review
No clinically important response to treatment ‐ ultra short term (at 12 hours) · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes no clinically important response to treatment ‐ ultra short term (at… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
2 findings from 1 review
No clinically important response to treatment ‐ short term · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes no clinically important response to treatment ‐ short term (3 weeks… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to adverse effects (overall tolerability… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review